About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...
Eswatini on Tuesday became the first African country to receive lenacapavir, the first twice-yearly HIV prevention injection hailed by global health officials as a game-changer in the fight against a ...
Proteomics helped uncover molecular signatures of multiple sclerosis up to seven years before symptom onset, paving the way ...
The ECDC says the region could still meet its testing targets for HIV, but that it will be harder to improve detection for ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Clinical Trials Arena on MSN
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback